Shares of Omnicell (NASDAQ: OMCL) surged 8.22% in pre-market trading on Thursday, following the company's announcement of better-than-expected third-quarter results and an improved full-year outlook. The healthcare technology company, known for its medication management solutions, demonstrated resilience in a challenging economic environment.

Omnicell reported adjusted earnings per share of $0.51 for Q3 2025, significantly beating the analyst consensus estimate of $0.36. While this represents a slight decrease from $0.56 per share in the same period last year, it showcases the company's ability to maintain profitability. Revenue for the quarter came in at $311 million, surpassing analyst expectations of $295.587 million and marking a 9.99% increase year-over-year.

The company's strong performance was primarily driven by its flagship point-of-care connected devices, along with growth in technical services, consumables, and SaaS offerings. In light of these positive results, Omnicell raised its full-year 2025 guidance, now projecting total revenues between $1.177 billion and $1.187 billion, and non-GAAP earnings per share of $1.63 to $1.73. This optimistic outlook, coupled with the company's strategic focus on transforming pharmacy care through robotics, smart devices, and analytics, has bolstered investor confidence, leading to the significant pre-market rally.